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Summary Statement – Utilising a mouse model of inflammatory bowel disease this article provides 
an improved understanding of the relative effects of GH/IGF-1 on bone health in experimental 
colitis. 
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Abstract 
 
Individuals with inflammatory bowel disease (IBD) often present with poor bone health. The 
development of targeted therapies for this bone loss requires a fuller understanding of the 
underlying cellular mechanisms. Although bone loss in IBD is multifactorial the altered sensitivity and 
secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in IBD is understood to be 
a critical contributing mechanism. The expression of suppressor of cytokine signaling 2 (SOCS2), a 
well-established negative regulator of GH signaling, is stimulated by pro-inflammatory cytokines. 
Therefore, it is likely that SOCS2 expression represents a critical mediator through which pro-
inflammatory cytokines inhibit GH/IGF-1 signaling and decrease bone quality in IBD.    
Utilising the DSS model of colitis we have revealed that endogenously elevated GH function in the 
Socs2-/- mouse protects the skeleton from osteopenia. Micro-computed tomography assessment of 
DSS treated wild-type mice revealed a worsened trabecular architecture compared to control mice. 
Specifically, DSS treated WT mice had significantly decreased bone volume (BV/TV) (41%; p<0.05), 
trabecular thickness (16%; p<0.05), trabecular number (30%; p<0.05), and a resulting increase in 
trabecular separation (19%; p<0.05). In comparison, the trabecular bone of Socs2 deficient mice was 
partially protected from the adverse effects of DSS.  The reduction in a number of parameters 
including BV/TV (21%; p<0.05) was less, and no changes were observed in trabecular thickness or 
separation. This protected phenotype was unlikely to be a consequence of improved mucosal health 
in the DSS treated Socs2-/- mice but rather a result of unregulated GH signaling directly on bone.  
These studies indicate that the absence of SOCS2 is protective against bone loss typical of IBD. This 
study also provides an improved understanding of the relative effects of GH/IGF-1 on bone health in 
experimental colitis, information that is essential before these drugs are explored as bone protective 
agents in children and adults with IBD. 
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Introduction 
Inflammatory bowel disease (IBD), which includes the chronic intestinal disorders, Crohn’s disease 
(CD) and ulcerative colitis (UC), is considered to result from an inappropriate inflammatory response 
to intestinal microbes in genetically susceptible hosts (Abraham and Cho, 2009). They are life-long 
conditions with a prevalence of 5 per 1000 people and annual health care costs exceeding $1.7 
billion in the United States (Sandler et al., 2002, Lakatos et al., 2006).  In addition, to the well-
recognized gut inflammation associated with IBD, both children and adults have poor bone health 
and are at increased risk of fractures which cannot solely be attributed to exogenous glucocorticoid 
exposure (Thearle et al., 2000; van Staa et al., 2003; Wong et al., 2016)).  The relative risk of fracture 
in adults is 40% higher than normal (Compston et al., 1987) and a vertebral fracture may be present 
in 10% of affected people (Laakso et al., 2012; Wong et al., 2014). Recent studies in children have 
also shown that trabecular bone density, which was reduced at diagnosis, showed inadequate 
improvement despite control of the underlying inflammation (Dubner et al., 2009).  These patients 
also have abnormal bone geometry with thinner and smaller bones (Dubner et al.,2009; 
Tsampalieros et al.,2013). Furthermore, peak bone mass is compromised in childhood onset IBD, 
despite adequate control of disease and progression through puberty (Laakso  et al., 2014). 
 
The etiology of bone loss in IBD is multifactorial, with risk factors including steroid medication, poor 
nutrient intake/absorption and the underlying inflammatory state (Bernstein et al., 2013). Central to 
the inflammatory response in IBD is the over production by T lymphocytes and macrophages of 
various pro-inflammatory cytokines such as interleukin (IL) -1, -2, -6, -8, and tumor necrosis factor 
(TNF)-α (Ali et al., 2009).  IL-6 has been identified as the predominant cytokine mediating the bone 
abnormalities, and genetic variations in IL-6 correlate well with the clinical course of IBD and the 
extent of bone loss (Schulte et al., 2000).  Although pro-inflammatory cytokines are known to 
promote bone loss directly, they also lead to altered sensitivity and secretion of growth hormone 
(GH) and insulin-like growth factor-1 (IGF-1) in IBD which may be another critical mechanism leading 
to osteoporosis (Wong et al., 2010). 
 
GH and IGF-1 are recognized stimulators of bone mass (Giustina et al., 2008). Transgenic mice over 
expressing Igf1 in osteoblasts exhibit increased trabecular bone, whereas Igf1 null mutants exhibit 
reduced cortical bone (Liu et al., 1993; Zhao et al., 2000). GHR-/- mice have reduced bone turnover, 
cross-sectional cortical bone area, and cortical growth, whereas GH overexpression results in 
increased bone cortical area (Sjogren et al., 2000; Sims et al., 2000; Eckstein et al., 2004).  Skeletal 
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manifestations are also observed in humans with GH deficiency who present with low bone turnover 
osteoporosis (Doga et al., 2005) which can be ameliorated by rhGH replacement therapy (Hansen et 
al.,1996).  The therapeutic benefits of rhGH administration on bone health of IBD patients remain 
unknown. Nevertheless, given that both rhGH and rhIGF-1 are available as therapeutic drugs, there 
is potential for these anabolic drugs to improve bone health in people with IBD.  
Suppressor of cytokine signaling 2 (SOCS2) regulates GH signalling during normal growth and 
development.  This physiological role is not restricted to bone. This function is most clearly observed 
in the Socs2 KO mouse where a number of organs are increased in size and these include liver, heart, 
lungs, bladder (Metcalf et al., Nature 2000).  In another study SOCS2 has been shown to limit 
intestinal growth (Michaylira et al., 2005).  SOCS2 is also induced by a subset of pro-inflammatory 
cytokines e.g. IL-6, IL-1b and TNFα which are elevated in IBD and mediate the inflammatory 
response (Starr et al., Nature 1997; Greenhalgh & Hilton Biol 2001; Rico-Bautista et al., 2006; 
Sanchez-Munoz et al,. 2008; MacRae et al., 2009). However, this protection against inflammation 
may come at the expense of poor bone health through the induction of SOCS2 and the inhibition of 
GH signalling (Denson et al., 2003; Shi et al., 2004).   
SOCS2 is expressed by many cells, including osteoblasts, and inhibits GH signaling via inhibition of 
the JAK/STAT intracellular signaling pathway (Greenhalgh et al., 2002; Flores-Morales et al., 2006; 
Michaylira et al., 2006, Pass et al., 2012, Dobie et al., 2014). Socs2 deficient mice, have unrepressed 
GH signaling and present with an overgrowth and high bone mass phenotype (Metcalf et al., 2000; 
MacRae et al., 2009; Dobie et al., 2014).  These data emphasize the critical role for SOCS2 in 
controlling GH’s anabolic effects on bone. Therefore, it is possible that increased osteoblast SOCS2 
expression represents a critical mediator through which pro-inflammatory cytokines inhibit GH/IGF-1 
signaling and decrease bone mass and quality in patients with IBD.   
To directly examine this, we studied bones from a mouse model of IBD using dextran sodium sulfate 
(DSS) induced colitis and investigated the potential of ablating the expression of Socs2 to 
endogenously elevate GH and IGF-1 function, and correct the bone loss observed in murine colitis. 
This study is the first-ever in an IBD animal model to investigate whether GH and IGF-1 have bone 
protective effects.  Furthermore, data from this innovative approach will help inform the design of 
novel therapies that are directed specifically at the mechanism of insult which leads to poor bone 
health in children and adults with IBD. 
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Results 
Effect of DSS treatment on body-weight of WT and Socs2-/- mice. 
To investigate the effects of DSS induced colitis on bone development and the possible role of SOCS2 
in mediating bone loss, WT and Socs2-/- mice were treated with 3% DSS for 4 days (Fig. 1). The dose 
and duration of DSS treatment was based on results from a dosing experiment where mice were 
given DSS at varying concentrations for 4-5 days (Fig. S1) During the DSS treatment period (0-4 days) 
no weight loss was observed in WT or Socs2-/- mice (Fig. 1).  Independent of genotype, mice exhibited 
a rapid weight loss from day 4 (Fig. 1). There was no significant difference in maximum weight loss 
observed between WT  (15%) and Socs2-/- (13%) mice (Fig. S1B). Following the period of weight loss, 
all DSS treated mice continued to gain weight to the end of the study (day 18) (Fig. 1). Pair fed 
control mice did not show any significant alterations in body weight throughout the experiment (Fig. 
1). During the period of DSS treatment, water intake was similar in WT and Socs2-/- mice. Also, food 
intake during DSS intake and the periods of weight loss and recovery were similar (data not shown).   
In terms of weight loss, WT mice showed high individual variation in susceptibility to DSS (Fig. S1C). 
Maximum body weight loss ranged from 6% to 21% in WT mice treated with 3% DSS. In contrast, 
body weight loss observed in Socs2-/- mice treated with 3% DSS was more uniform, ranging from 11% 
to 15% before recovering (Fig. S1C).  
Effect of DSS treatment on longitudinal growth of WT and Socs2-/- mice. 
Socs2-/- mice are characterised by their overgrowth phenotype (Greenhalgh et al., 2002).  In 
agreement with this, the untreated Socs2-/- mice at the end of this study (day 18) were 39% 
(p<0.001) heavier than untreated WT mice (Table 1). Also, tibia (6%; p<0.01), and femur (8%; p<0.01) 
length as well as nose to rump length (13%; p<0.001) were all greater in untreated Socs2-/- mice 
compared to WT mice (Table 1).  DSS treatment had no effect on the body-weight of WT and Socs2-/- 
mice at the end of the study (Table 1). Similarly, DSS treatment did not result in altered nose to rump 
length, tibia length, or femur length of WT or Socs2-/- mice (Table 1).   
Colon pathology of DSS treated mice 
To assess the effects of DSS on mucosal integrity, detailed histological analysis was performed on the 
colon from control and DSS treated WT and Socs2-/- mice. Histology scores were minimal in the non-
DSS treated (control) mice and furthermore, there were no notable differences in colon diameter, 
morphological differences or differences in histological scoring between the non-DSS treated 
(control) WT and Socs2-/- mice (Fig.2A, B&C).  This infers that the ablation of Socs2 alone had no 
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obvious effects on colon morphology. In contrast, histological analysis of the colon from DSS treated 
WT and Socs2-/- mice, revealed extensive levels of inflammation. DSS treated mice were 
characterised as having signs of both acute and chronic inflammation throughout their colon (Fig. 
2A). Signs of acute inflammation included infiltration of neutrophils into the lamina propria and 
submucosa (Fig. 2A), and epithelial degeneration (Fig. S2). In a number of sections there were also 
signs of crypt loss (Fig. S2). In addition to acute inflammation, there were also high levels of 
mononuclear leucocytes (macrophages, lymphocytes and plasma cells) (Fig. 2A & Fig. S2), and 
transmural inflammation (Fig. S2), which are recognised markers of chronic inflammation.  
Scores for inflammation severity and extent of inflammation were significantly increased in DSS 
treated mice (Fig. 2B). However, the histological mean scores for inflammation severity (WT: 6.8, 
Socs2-/-: 5.2) and extent of inflammation (WT: 7.4, Socs2-/-: 6.0) following DSS treatment were not 
significantly different between genotypes, nor was colon diameter (Fig. 2B&C). In contrast, there 
was a significant difference in crypt damage/regeneration mean score between DSS treated WT and 
DSS treated Socs2-/- mice (p<0.05) (Fig. 2B). This difference in crypt damage/regeneration between 
genotypes following DSS treatment was not sufficient however to alter total pathology scores 
indicating that the absence of Socs2 was unable to confer overall protection against DSS induced gut 
inflammation (Fig. 2B).  Although not part of the scoring system, the number of goblet cells in the 
mucosa of the colon was reduced in areas of loss of the epithelium as a result of the inflammatory 
response, and in areas of crypt damage and regeneration in DSS-treated WT and Socs2 deficient 
mice.  
 
Systemic IGF-1 levels in DSS treated mice  
GH resistance has been associated with IBD, and is characterized by a decrease in systemic IGF-1 
levels (Ballinger et al., 2000; Katsanos et al., 2001). Analysis of serum from DSS treated animals 
revealed that IGF-1 levels were similar in control and DSS treated WT (WT control 263.8 ± 6.2ng/ml; 
DSS treated WT 243.6 ± 10.8ng/ml) and Socs2-/- mice (Socs2-/- control 264 ± 9.8ng/ml; DSS treated 
Socs2-/- 276.9 ± 17.6ng/ml).  
Socs transcript levels in bones of DSS treated mice  
Socs1, 2, and 3 transcript levels were measured in bone samples from control and DSS treated WT 
mice. Socs2 (2.7 fold; p<0.05) and Socs3 (4.1 fold; p<0.05) levels were higher in DSS treated mice, but 
no significant difference was observed in Socs1 levels (Fig. 3).   
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Bone phenotype of DSS treated mice   
DSS induced colitis has previously been shown to have detrimental effects on bone quality, in both 
juvenile (4 week old) and young adult (10 week old) mice (Hamdani et al., 2008; Harris et al., 2009). 
In accordance with these studies, DSS treated WT mice showed worsened trabecular architecture 
compared to control mice as demonstrated by μCT (Fig 4).  Specifically, DSS treated WT mice had 
significantly decreased bone volume/tissue volume (BV/TV) (41%; p<0.05), trabecular thickness 
(16%; p<0.05), and trabecular number (30%; p<0.05), and a resulting increase in trabecular 
separation (19%; p<0.05) (Fig. 4). The increase in trabecular pattern factor (40%; p<0.05) and 
structural model index (14%; p<0.05) indicates a more disconnected ‘rod-like’ trabecular structure, 
which are associated with reduced trabecular micro-architecture quality (Hildebrand and 
Rüegsegger, 1997). In comparison, DSS treated Socs2-/- mice showed a much less severe alteration in 
trabecular architecture compared to control mice (Fig. 4). Specifically, the reduction in BV/TV (21%; 
p<0.05) and trabecular number (14%; p<0.05), and increase trabecular pattern factor (19%; p<0.05) 
and structural model index (6%; p<0.05) were between 50%-55% less severe than that noted in DSS 
treated WT mice (Fig 4B). Furthermore, trabecular thickness and trabecular separation, in contrast 
to DSS treated WT mice, were not significantly different in DSS treated Socs2-/- mice compared to 
controls (Fig 4B).  These striking data indicate that the level of bone loss in DSS colitis is influenced 
by Socs2 expression and furthermore suggest that the absence of SOCS2 is partially protective 
against bone loss typical of IBD.  
Analysis of cortical bone in control and DSS treated WT and Socs2 deficient mice revealed no change 
in any parameters following DSS treatment (Table 2).  Nonetheless, the anabolic bone phenotype 
(characterized by increased cortical tissue area (p<0.05), bone area (p<0.05), cortical thickness 
(p<0.05), and marrow area (p<0.05) was apparent in untreated Socs2-/- mice (Table 2). 
Discussion 
Murine models of IBD have been used extensively to better understand disease etiology and 
therapeutic opportunities. In this study we used the DSS-induced colitis mouse model which has 
been extensively validated by others to induce acute and chronic forms of IBD (Wirtz et al., 2007; De 
Roberts et al., 2011; Kanneganti et al., 2011). This model has also been used to study the link 
between IBD and the risk of colorectal cancer (Bollrath et al., 2009). The strength of this model is 
that histological changes seen can include a wide range of features that are associated with chronic 
forms of IBD in man (Perse and Cerar, 2012). DSS induced colitis is the result of deterioration of the 
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epithelial barrier through an increase in epithelial cell apoptosis and a decrease in proliferation 
(Araki et al.,2010). This deterioration allows for the influx of antigens and micro-organisms; 
prompting an increased expression of inflammatory mediators (e.g. TNF-α, IL-1β, IFN-γ, IL-10, IL-6 
and IL-12) which drive the pathogenesis of DSS-induced colitis (Tlaskalova-Hogenova et al., 2005; 
Perse and Cerar, 2012).  
 
DSS induced acute colitis has previously been shown to result in reduced bone health in juvenile and 
young adult mice. During active disease and early recovery in juvenile mice, both the trabecular and 
cortical bone compartments are adversely affected whereas DSS-treated older mice exhibit reduced 
femoral bone mass and altered micro architecture.  No changes were observed in cortical bone 
indices (Hamdani et al., 2008; Harris et al., 2009).   
In the present study we found a severe trabecular bone loss phenotype in WT mice treated with DSS, 
but no changes in cortical bone parameters. These data are consistent with previous reports in 
similarly aged adult mice (Hamdani et al., 2008). The trabecular bone phenotype was characterized 
by lowered BV/TV, trabecular thickness, trabecular number and increased trabecular separation. 
Taken together, these studies suggest that there is an age-specific effect of DSS induced IBD on bone 
loss in mice. During early puberty (3 to 5 weeks) there is extensive radial bone expansion and this 
may explain why the loss of cortical bone is restricted to juvenile mice (Callewaert et al., 2010). DSS 
treatment did not result in altered nose to rump length, tibia length, or femur length of WT or Socs2-
/- mice.  This is contrast to a previous study which reported decreased bone length and growth plate 
thickness and altered chondrocyte marker gene expression in young mice (four-week-old) treated 
with DSS (Harris et al., 2009).  Whilst bone length was fully restored at the end of the study these 
data are in accord with human studies that show IBD can stunt growth and diminish final height 
(Burnham 2004; Sylvester et al., 2007).  It is likely that we did not see a reduction in bone length in 
this study due to the older mice (8-9 weeks of age) studied by which time the rapid phase of linear 
bone growth was completed. 
SOCS2 expression is induced by pro-inflammatory cytokines and is a recognized inhibitor of GH 
signaling (Denson et al., 2003). Furthermore, Socs2 deficient mice have uninhibited GH signaling, 
leading to increased body-weight and a high bone mass phenotype (Metcalf et al., 2002; MacRae et 
al., 2009; Dobie et al., 2014).  GH is a recognized stimulator of bone mass (Giustina et al.,2008). 
Global GH overexpression results in increased cortical cross-sectional area (Eckstein et al., 2004). 
Increased cortical area and bone strength is also observed in human growth hormone transgenic 
mice, where expression of GH is directed specifically to osteoblasts with minimal systemic 
overproduction (Tseng et al., 1995) Conversely, mice carrying mutations of the GH receptor have 
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reduced femoral width and tibial cortical thickness, and an associated reduction in periosteal bone 
growth (Sims et al., 2000). Skeletal manifestations are also observed in humans with GH-deficiency 
who present with low bone turnover osteoporosis, leading to increased fracture risk (Doga et al., 
2014). Using an osteoblast culture model we have previously shown that GH’s promotion of STAT5 
phosphorylation and nuclear translocation is enhanced in Socs2 deficient osteoblasts, whereas Socs2 
overexpression in osteoblasts blunts GH’s effect (Dobie et al., 2014). These observations stress the 
key role for SOCS2 in controlling GH’s anabolic skeletal effects and are extended by data from this 
present study which reveals that Socs2 expression is higher in bone samples from DSS treated WT 
mice.  This increased Socs2 expression, a probable consequence of higher levels of circulating pro-
inflammatory cytokines, is likely to repress GH signaling and contribute to the poor bone health 
noted in colitic (DSS treated) WT mice.   
 
In this study, we examined the hypothesis that elevated GH signaling in mice deficient in SOCS2 
protein would offer protection against bone loss in a murine model of IBD.  Such protection was 
observed in trabecular bone where in the absence of SOCS2, DSS treatment resulted less severe 
changes to the trabecular bone architecture. This underscores the importance of Socs2 ablation in 
protecting against bone loss in DSS induced IBD. Complete protection of the skeleton was not 
observed however, and this is likely due to other cellular mechanisms including, increased 
osteoclastic resorption, direct (non-GH mediated) effects of pro-inflammatory cytokines on 
osteoblast differentiation/function and diminished GH signaling through elevated Socs3 levels. The 
effects of ablating both Socs2 and Socs3 in the DSS model would be of interest as it may offer 
enhanced protection to the skeleton.  Previous studies have shown that the removal of GH signaling 
deletes the Socs2-/- phenotype which includes the normalisation of body weight and bone length 
(Greenhalgh et al., 2002, 2005).  Therefore, it is likely that mice in which both Socs2 and GH signaling 
are silenced there would be no protection from DSS induced bone loss. The gathering of such 
evidence would provide functional evidence for GH’s pivotal role in protecting bone health in this 
animal model of IBD. Furthermore, it is also worth noting that reduced expression of SOCS2 has 
been associated with increased cancer risk which may be a consequence of increased GH signalling 
(Hendriksen et al., 2006).  Therefore, if GH treatment or novel therapies to target the SOCS2 protein 
are to be considered as bone protective agents in children and adults with IBD then the potential 
cancer risk has to be carefully considered. 
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Histologic scoring in the present study was carried out using a validated scoring scheme, allowing an 
in depth assessment of the mucosal integrity (Dieleman et al., 1998; Williams et al., 2001).  Acute 
and chronic colitis are characterised by distinct pathological changes to the colon. Acute 
inflammation is associated with an influx of neutrophils into the lamina propria, and in some cases 
epithelial degeneration. Chronic inflammation on the other hand is associated with mononuclear 
leukocyte infiltration, crypt architectural disarray, and crypt regeneration (Melgar et al., 2005; Perse 
& Cerar 2012). In this study, histological analysis revealed signs of both acute and chronic 
inflammation in the colons of all DSS treated mice, suggesting that the current experimental design 
was sufficient to induce chronic inflammation. Previous reports have shown that acute inflammation 
can progress to chronic in C57BL/6 mice following a single treatment of DSS (Melgar et al., 2005). 
Importantly, little difference was observed between the pathology scores of colons from DSS treated 
WT and Socs2-/- mice.  This pathological assessment suggests that the absence of SOCS2 does not 
appear to protect against the deterioration of mucosal integrity in DSS experimental colitis and 
therefore the improved bone health noted in the DSS treated Socs2 deficient mice is unlikely to be 
solely attributed to improved disease status.  However, it is recognised that further studies to 
quantify cell apoptosis, proliferation and stem cell number within the colon would allow us to make 
a more definitive judgement on colon health in the DSS treated WT and SOCS2 deficient mice. 
 
Intriguingly, there have been reports that increased GH activity promotes mucosal repair during IBD 
associated inflammation. A small clinical trial of patients with active CD reported that therapy with 
recombinant human GH therapy improved the CD activity index, and decreased the need for other 
medication (Slonim et al., 2000).  Previous studies have also reported that in mice with a mutated 
gp130 receptor (gp130Y757F mice) there is protection to the colon from the damaging effects of DSS 
(Bollrath et al., 2009).  It is possible that in the gp130Y757F mice in which SOCS3 cannot inhibit 
JAK/STAT signaling there is a protective pathway(s), involving increased STAT3 activation that may 
not be active in SOCS2 deficiency.  
Furthermore, GH transgenic mice display a similar extent of colon pathology during the onset of 
inflammation compared to WT mice, but show improved mucosal repair over an extended time 
period (Williams et al., 2001).  Increased mucosal repair in the GH transgenic mice may be a result of 
increased systemic IGF-1, which has been reported to partially attenuate colonic damage in the DSS 
rat model (Mathews et al.,1988; Howarth et al.,1998).   Whilst we noted subtle improvements in the 
crypt damage/regeneration score of DSS treated Socs2-/- mice this is unlikely to be related to 
systemic IGF-1 status of these mice, which were found to be normal. However, it must be noted that 
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gut IGF-1 levels were not measured in these mice. Therefore the possibility of local upregulation of 
IGF-1 in response to unregulated GH signalling in Socs2-/- mice cannot be ruled out.  Despite the 
slight improvement in the crypt damage/regeneration score of DSS treated Socs2-/- mice, their total 
pathology score was similar to DSS treated WT mice.  It is however prudent to note that in our 
studies systemic IGF-1 levels were measured at the end of the experiment when the DSS treated 
animals presented with severe inflammation of the colon, but had recovered their body-weight. 
Previous studies have shown decreased systemic IGF-1 levels with active disease which returned to 
normal with recovery (Harris et al., 2009). Further studies are required to understand fully the role 
of systemic IGF-1 in the skeletal response to experimental IBD. In keeping with previous research, 
systemic IGF-1 levels in WT and Socs2-/- control animals were comparable, further confirming the 
importance of the direct anabolic effects of GH on bone (Metcalf et al., 2000; Lorentzon et al., 2005; 
MacRae et al., 2009; Dobie et al., 2014, Dobie et al., 2015).  
 
The negative effects of increased Socs2 expression in inflammatory conditions may not be restricted 
to the skeleton.  In rodent models of chronic kidney disease there is increased Socs2 gene expression 
in liver and muscle which may contribute to impaired phosphorylation and nuclear translocation of 
GH-activated STAT proteins and the development of GH resistance (Schaefer et al., 2001, Sun et al., 
2004; Mak and Cheung 2007, Cheung et al., 2008).  Intervention strategies to reduce uremic 
cachexia are associated with amelioration of the uremia-associated increase in Socs2 expression 
(Cheung et al.,2008). Recent data has also shown that Socs2 deletion protects against 
streptozotocin-induced type 1 diabetes in adult male mice possibly through increased β-cell 
hypersensitivity to GH (Alkharusi et al.,2015).  It is therefore likely that SOCS2 signaling represents a 
generic critical pathway through which pro-inflammatory cytokines alter both GH/IGF-1 signaling 
and cellular function (Ahmed and Farquharson, 2010; Farquharson and Ahmed, 2013). 
 
In conclusion, these studies suggest that the absence of SOCS2 is protective against bone loss typical 
of IBD and are consistent with the premise that increased osteoblast SOCS2 expression represents a 
critical mediator through which pro-inflammatory cytokines inhibit GH signaling and decrease 
osteoblast function and bone accrual.  This study also provides an improved understanding of the 
relative effects of GH/IGF-1 on bone health in experimental colitis and is consistent with data 
reporting the beneficial effects of GH on bone in conditions such as juvenile idiopathic arthritis 
(Bechtold et al. 2009).  This accumulation of information is essential before these drugs are explored 
as bone protective agents in children and adults with IBD.  
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Materials and Methods   
Mice  
It is recognised that different genetic strains of mice respond differently to DSS (Melgar et al., 2005; 
Perse and Cerar 2012). Therefore, we backcrossed our original SOCS2 knockout (KO) mice (76.0% 
C57BL/6) (MacRae et al., 2009) with pure C57BL/6 mice a further six-times to establish our SOCS2 KO 
mice and litter mate wild-type (WT) controls on a pure (>99.0%) C57BL/6 background strain.  These 
mice were used in all studies reported.  For genotyping, ear biopsied DNA was analysed by PCR for 
SOCS2 (WT) or the neocassette (Socs2-/-) using the following primer sequences:  SOCS2 - Forward (5'-
3') TGTTTGACTGAGCTCGCGC,   Reverse (5'-3') CAACTTTAGTGTCTTGGATCT and Neo - Forward (5'-3') 
ACCCTGCACACTCTCGTTTTG Reverse (5'-3') CCTCGACTAAACACATGTAAAGC.  Primers were obtained 
from Eurofins MWG Operon, London, UK.  All animal experiments were approved by Roslin 
Institute’s Animal Users Committee, and the animals were maintained in accordance with Home 
Office (UK) guidelines for the care and use of laboratory animals. 
Establishment of acute DSS induced colitis model 
Male WT and Socs2 KO mice (6 mice per group), 8-9 weeks of age, received 3.0% DSS (molecular 
weight ~40000kD; Sigma Aldrich, UK) in their drinking water (tap water). They were given DSS 
treated water ad lib for 4 days, following which they received normal tap water for a 14 day recovery 
period. Control (non DSS treated) male WT and Socs2 KO mice (6 mice per group) were offered 
normal tap water for the duration of the study. The health status of the DSS treated mice was scored 
daily, with particular attention paid to their coat condition, mobility, blood in stools and eye clarity. 
Body weights of all mice were recorded daily.  To establish the weight loss that was due to 
inflammation and not lowered food intake, the mice were pair-fed.   The quantity of food consumed 
daily (fed ad lib.) by the DSS treated mice was weighed and then provided to control animals (who 
received no DSS) the following day (Ballinger et al., 2000).  All mice were housed individually to allow 
accurate measurement of food and water intake and health status.  Eighteen-days after the 
initiation of the studies the experiment was stopped, blood collected for serum analysis, and the 
long bones and the colon dissected. 
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Colon histology 
The colon was dissected from WT and Socs2-/- mice ± DSS treatment and fixed and stored in 4% 
paraformaldehyde. Each colon was divided into 5 transverse segments including proximal to distal 
portions. Tissue processing, wax embedding, sectioning (5µm thick) and H&E staining were done 
following routine procedures. Colon pathology was graded blind on sections from all 5 segments of 
each mouse using an established histological grading scheme (Dieleman et al., 1998). Segments of 
colon were assessed separately for inflammation.  Scores from all five segments were averaged to 
provide an overall pathology score. Colon diameters were measured on the H&E sections. Using 
image analysis software the diameter of each transverse segment was measured twice and 
averaged.  
 
Microcomputed tomography 
 
To evaluate trabecular architecture and cortical bone geometry of the tibia from control and DSS 
treated mice we used a µCT system (Skyscan 1172 X-Ray microtomograph, Bruker Corporation, 
Kontich, Belgium) as described previously (Dobie et al.,2014).  In brief,  high-resolution scans with an 
isotropic voxel size of 5 µm (trabecular bone) or 10 µm (cortical bone) were acquired (60 kV, 0.5 mm 
aluminium filter, 0.6° rotation angle). Two images were averaged at each rotation angle. Scan 
reconstruction was done using NRecon software (Bruker). A 1 mm section of the metaphysis was 
taken for the analysis of trabecular bone, using the base of the growth plate as a standard reference 
point. A 500 µm section of the mid-shaft was taken for the analysis of cortical bone, using the 
articulation with the fibula as a standard reference point. CTAn software (Bruker) was used to 
analyse the appropriate parameters (Bouxsein et al., 2010). 
 
Serum IGF-1 ELISA 
Blood obtained by cardiac puncture was stored in serum tubes (Greiner Bio-One, Gloucestershire, 
UK) on ice for over 30mins to allow for clotting. Following  centrifugation for 10 mins at 1000g, 
supernatant was removed, aliquoted, and stored at -80°C. IGF-1 levels were assessed by ELISA 
(Quantikine, R&D Systems, Minneapolis, USA) according to manufacturer’s instructions.  
RNA extraction and RT-qPCR analysis   
Left femur were dissected from WT and Socs2-/- mice ± DSS treatment. The femurs had both 
epiphyses removed and the marrow was spun out by centrifugation and discarded. The bone 
samples were snap frozen in liquid nitrogen and stored at -80°C. Bone samples were ground using a 
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mortar and pestle, and homogenised by a hand held homogeniser in QIAzol Lysis Reagent. RNA from 
extracted using an RNeasy Lipid Tissue Kit (Qiagen Ltd, Manchester UK) following manufacturer’s 
protocol. RNA content was measured by absorbance at 260 nm, and quality by 260/280 ratios. RNA 
was stored at -80°C. RT was carried out as described previously (Newton et al 2014).  RT-qPCR was 
performed using the SYBR green (Roche detection method on a Stratagene Mx3000P real-time qPCR 
machine with MxPro software (Stratagene, Santa Clara, CA, USA).  Relative gene expression was 
calculated using the DDCt method (Livak and Schmittgen, 2001). Each cDNA sample was normalized 
to housekeeping gene gapdh (Primer Design, Southampton, UK).  Reactions were performed with 
gene of interest primers - Socs1 (For– TCCGATTACCGGCGCATCACG; Rev– 
CTCCAGCAGCTCGAAAAGGCA), Socs2 (For – TGGCTGCTCAAGATCAAATG; Rev-
TGTCCTCCTGGAAATGGAAG) and Socs3 (For- GAGTACCCCCAAGAGAGCTTACTA; Rev- 
CTCCTTAAAGTGGAGCATCATACTG) (MWG Eurofins).  
 
Statistical analysis 
All measurements and analysis were done blinded to the researcher.  All statistical analysis was 
completed using GraphPad Prism. Final measurements, IGF-1 ELISA, and histology scoring data were 
analysed using a two-tailed unpaired t-test with Welch’s correction (equal standard deviations not 
assumed) or suitable nonparametric test (Mann-Whitney) if the data were not normally distributed. 
Due to small sample size transcript and μCT data were analysed using a nonparametric test (Mann-
Whitney). Data presented as mean ± SEM.   
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Figures 
 
 
 
Figure 1. Body weight changes of WT and Socs2-/- mice treated with DSS followed by recovery 
period. Percentage change in body weight of WT and Socs2-/- mice treated with 3% DSS for 4 days. 
Data presented as mean ± SEM (n=6).   
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Figure 2. Colon pathology of DSS treated WT and Socs2-/- mice.  A. Representative H&E stained 
sections of colon from control and DSS treated WT and Socs2-/- mice. B. Diameter of DSS treated, and 
control WT and Socs2-/- colons. Numbers 1-5 represent difference segments along the colon. C. 
Histological scoring of DSS treated, and control WT and Socs2-/- colons. Data presented as mean ± 
SEM (n=6). asignificantly different from DSS treated WT mice p<0.05; by unpaired t-test or 
nonparametric test (Mann-Whitney).  
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Figure 3. Socs mRNA expression in bone from DSS treated WT mice.  Socs1, 2, and 3 mRNA 
expression levels in tibia from DSS treated WT mice compared to control mice at day 18 (endpoint) 
of DSS study. Data presented as mean ± SEM. Control group n=6, DSS treated group n=4. 
asignificantly different from control samples, p<0.05; by nonparametric test (Mann-Whitney).    
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Figure 4. – Trabecular bone architecture of DSS treated WT and Socs2-/- mice. A. Representative 3D 
μCT reconstructions showing a less compact trabecular architecture resulting in a more porous 
structure (*) in DSS treated WT mice compared to WT control mice.  A similar alteration in bone 
architecture was not observed in DSS treated Socs2
 
deficient mice. B. Percentage change of 
trabecular parameters in DSS treated mice relative to genotype-matched controls. Data presented as 
mean ± SEM (n=4). asignificantly different from genotype-matched control, p<0.05; by 
nonparametric test (Mann-Whitney).  
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Table 1.  Weight and length measurements of WT and Socs2-/- mice at day 18 of DSS study.  
 
N to R length = nose to rump length. Data presented as mean ± SEM. All groups n=6 except Socs2-/- 
control femur (n=5).   asignificantly different from WT control mice, p<0.01, b significantly different 
from WT control, p<0.001; by unpaired t test.   
 
Table 2.  Cortical bone parameters of tibia from control and DSS treated WT and Socs2-/- mice at day 
18 of DSS study. 
 
Tt.Ar = total tissue area, Ct.Ar = cortical bone area, Ma.Ar = medullary area, Ct.Th = cortical 
thickness. Data presented as mean ± SEM (n=4) asignificantly different from WT control mice, 
p<0.05; by nonparametric test (Mann-Whitney).  
  
 WT  Socs2-/- 
 Control  DSS Treated  Control   DSS Treated 
Weight (g) 23.5 ± 0.34  22.6 ± 0.38  32.6 ± 0.38b  31.5 ± 0.46 
N to R Length (mm) 88.7 ± 1.11  87.9 ± 1.40  100.5 ± 1.15b  103.2 ± 1.35 
Tibia (mm) 17.7 ± 0.14  17.6 ± 0.16  18.7 ± 0.18a  18.9 ± 0.10 
Femur (mm) 14.4 ± 0.21  14.4 ± 0.10  15.6 ± 0.08a  15.2 ± 0.20 
 WT  Socs2-/- 
 Control DSS Treated  Control DSS Treated 
Tt.Ar (mm²) 0.84 ± 0.001 0.82 ± 0.002  1.03 ± 0.003a 1.01 ± 0.003 
Ct.Ar (mm2) 0.54 ± 0.014 0.54 ± 0.012  0.67 ± 0.028a 0.65 ± 0.022 
Ma.Ar (mm²) 0.30 ± 0.005 0.28 ± 0.005  0.37 ± 0.009a 0.36 ± 0.001 
Ct.Th (mm) 0.23 ± 0.003 0.23 ± 0.004  0.25 ± 0.008a 0.25 ± 0.006 
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